Adaptive Biotechnologies Equity 2025

Adaptive Biotechnologies Aktienanalyse

What does Adaptive Biotechnologies do?

Adaptive Biotechnologies Corp is a biotechnology company specializing in the discovery and development of therapies for various diseases. It was founded in 2009 by brothers Chad and Harlan Robins in Seattle, USA. Adaptive Biotechnologies Corp is a leading provider of immune sequencing technology and analysis of T-cell and B-cell receptors. The company's business model is based on the development of therapies through the analysis of patient samples. The company's artificial intelligence and machine learning make immune systems visible to fight pathogens. By creating an accurate profile of patients' immune systems, the company enables the development of personalized therapies tailored to the individual needs and disease profiles of patients. The company is divided into several divisions, including oncology, immunology, and research and development of therapeutics. In the field of oncology, Adaptive Biotechnologies Corp focuses on the discovery of cancer therapies by identifying T-cell receptor characteristics of patients who have responded to cancer treatments. The team at Adaptive Biotechnologies Corp works with various pharmaceutical and biotech companies to advance the discovery of cancer therapeutics. In the field of immunology, the company has also focused on the identification of rare and severe immune disorders to enable more targeted diagnostics and treatment. Adaptive Biotechnologies Corp provides immune and other research instruments and sample processing systems for the study of antigen-antibody interactions. In addition, the company has also developed its own products, including the ImmunTraCkeR® test system, which analyzes the immune response of critically ill patients to improve ongoing therapies or enable early detection of new diseases. Other products include the immunoSEQ® assay kit and the clonoSEQ® assay kit, which are used for sequencing patients' immune systems. These test systems allow for the detection of minimal residual routes of T-cell or B-cell receptors in patients' blood, enabling better monitoring of cancer and the creation of personalized treatment plans. Adaptive Biotechnologies Corp is particularly highly regarded in the pharmaceutical and biotech industry for novel therapeutics and biologics, and has already collaborated with many reputable companies including Genentech, Roche, and Microsoft. The company's mission is to accelerate progress in medical research and the development of new therapies to help patients around the world. In recent times, the company has played a crucial role in testing point-of-care COVID rapid tests. For example, it is working with universities such as the University of Pennsylvania to explore ways in which the tests can be utilized. The company is also developing its own COVID-19 tests that have undergone clinical testing. Overall, Adaptive Biotechnologies Corp is a successful biotechnology company with a unique focus on personalized medicine and therapies tailored to specific patient immune profiles. With its innovative products and services, as well as partnerships with industry leaders, the company has revolutionized the bio-IT world and become one of the leading companies in the industry. Adaptive Biotechnologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Adaptive Biotechnologies's Equity

Adaptive Biotechnologies's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Adaptive Biotechnologies's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Adaptive Biotechnologies's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Adaptive Biotechnologies's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Adaptive Biotechnologies’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Adaptive Biotechnologies stock

What is the equity of Adaptive Biotechnologies this year?

Adaptive Biotechnologies has equity of 202.71 M USD this year.

What was the equity of Adaptive Biotechnologies compared to the previous year?

The equity of Adaptive Biotechnologies has increased/decreased by -34.27% decreased compared to the previous year.

What impact does a high equity have on investors of Adaptive Biotechnologies?

A high equity is advantageous for investors of Adaptive Biotechnologies as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Adaptive Biotechnologies?

A low equity can be a risk for investors of Adaptive Biotechnologies, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Adaptive Biotechnologies affect the company?

An increase in equity of Adaptive Biotechnologies can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Adaptive Biotechnologies affect the company?

A reduction in equity of Adaptive Biotechnologies can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Adaptive Biotechnologies?

Some factors that can affect the equity of Adaptive Biotechnologies include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Adaptive Biotechnologies so important for investors?

The equity of Adaptive Biotechnologies is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Adaptive Biotechnologies take to change the equity?

To change equity, Adaptive Biotechnologies can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Adaptive Biotechnologies pay?

Over the past 12 months, Adaptive Biotechnologies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adaptive Biotechnologies is expected to pay a dividend of 0 USD.

What is the dividend yield of Adaptive Biotechnologies?

The current dividend yield of Adaptive Biotechnologies is .

When does Adaptive Biotechnologies pay dividends?

Adaptive Biotechnologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adaptive Biotechnologies?

Adaptive Biotechnologies paid dividends every year for the past 0 years.

What is the dividend of Adaptive Biotechnologies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adaptive Biotechnologies located?

Adaptive Biotechnologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adaptive Biotechnologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adaptive Biotechnologies from 10/10/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/10/2025.

When did Adaptive Biotechnologies pay the last dividend?

The last dividend was paid out on 10/10/2025.

What was the dividend of Adaptive Biotechnologies in the year 2024?

In the year 2024, Adaptive Biotechnologies distributed 0 USD as dividends.

In which currency does Adaptive Biotechnologies pay out the dividend?

The dividends of Adaptive Biotechnologies are distributed in USD.